title: Dual Immunity Concomitantly Suppresses HIV-1 Progression.
abstract: Broadly neutralizing antibodies (bnAbs) elicited in HIV-1+elite neutralizers typically are unable to reduce viremia in the same individuals from whom they are isolated. A recent study reports the development of bnAbs in an elite controller that, along with the help of T cells, were associated with restricting HIV-1 progression.
authors.affiliation: Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Department of Biotechnology, Faridabad, Haryana 121001, India.
authors.forename: Huma
authors.initials: H
authors.lastname: Qureshi
authors.affiliation: Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Department of Biotechnology, Faridabad, Haryana 121001, India; International AIDS Vaccine Initiative, New York, NY, USA. Electronic address: JBhattacharya@thsti.res.in.
authors.forename: Jayanta
authors.initials: J
authors.lastname: Bhattacharya
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology; D057134:Antibodies, Neutralizing / Q000096:biosynthesis / Q000276:immunology*; D018450:Disease Progression; D015483:HIV Antibodies / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology* / Q000503:physiopathology; D015497:HIV-1 / Q000235:genetics / Q000276:immunology* / Q000502:physiology; D006801:Humans; D014766:Viremia / Q000276:immunology; D014779:Virus Replication
chemical_list: D057134:Antibodies, Neutralizing; D015483:HIV Antibodies